Evidence map›Paper›PMID 40268824›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2025

Host Biomarkers and Antibiotic Tissue Penetration in Sepsis: Insights from Moxifloxacin.

Maria Sanz-Codina, Hartmuth Nowak, Markus Zeitlinger

Abstract read
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maria Sanz-CodinaDepartment of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0002-1687-5296
Hartmuth NowakDepartment of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus, Bochum, Ruhr-University Bochum, In der Schornau 23-25, 44892, Bochum, Germany.
Markus ZeitlingerDepartment of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. markus.zeitlinger@meduniwien.ac.at.

Funding

HORIZON EUROPE Marie Sklodowska-Curie Actions 861323
6 · The paper itself

Abstract

BACKGROUND AND

objectiveSepsis-induced pathophysiological changes may lead to pharmacokinetic variability which alters antibiotic concentrations at the host infection site. This poses a challenge in clinical practice, as sufficient antibiotic concentrations in tissue are necessary to effectively eradicate bacterial pathogens. In this exploratory study, we aimed to evaluate the potential of routinely used laboratory biomarkers to predict subcutaneous and muscle tissue penetration of moxifloxacin in septic patients.

methodsWe retrospectively analyzed data from 10 septic patients included in a pharmacokinetic study, in which moxifloxacin concentrations in subcutaneous adipose and muscle tissues were measured with microdialysis. We correlated the tissue-to-plasma ratio and protein binding with various clinical biomarkers.

resultsOur results revealed significant correlations for CRP, LDH, BUN, GPT, and total protein with moxifloxacin subcutaneous penetration, and BUN, GOT, and GPT with muscle penetration. Notably, all biomarkers except CRP correlated negatively with tissue penetration. Moreover, we found a positive correlation between moxifloxacin protein binding and total plasma proteins and albumin.

conclusionBiomarker tissue correlations suggest that the penetration of moxifloxacin into tissues is a complex process influenced by factors like inflammation, tissue integrity, liver function, protein levels, and renal function. Understanding these interactions might help optimize antibiotic dosing strategies.

Indexed as

Anti-Bacterial AgentsMoxifloxacinSepsisAdultAgedBiomarkersFemaleHumansMaleMicrodialysisMiddle AgedMuscle, SkeletalRetrospective StudiesTissue DistributionAnti-Bacterial AgentsBiomarkersMoxifloxacin

Identifiers

PMID40268824
PMCPMC12227375

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.